Clinical trials: psoriasis
Psoriasis
Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis
The primary objective of Study M16-009 was to investigate the safety of risankizumab in participants with moderate to severe chronic plaque psoriasis who were receiving long-term treatment.
- Trial name
- NCT02203851
- Testing
- Risankizumab
- Volunteers
- 110 people
- Sponsor
- AbbVie
Psoriasis
PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to Etanercept
The purpose of this study is to test the safety and effectiveness of infliximab in patients with plaque psoriasis who have been receiving the drug etanercept for treatment of their plaque psoriasis for at least four months…
- Trial name
- NCT00527072
- Testing
- infliximab
- Volunteers
- 217 people
- Sponsor
- Centocor Ortho Biotech Services, L.L.C.
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis, Arthritic
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
- Trial name
- SPIRIT-P1 (NCT01695239)
- Testing
- Ixekizumab, Adalimumab
- Where
- 116 sites in United States, Belgium and 13 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Chronic Plaque-Type Psoriasis
4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
CAIN457A2304E1 was an extension study to two phase III studies, CAIN457A2304 and CAIN457A2307 (core studies). This extension study planned to collect up to four years of long-term safety, tolerability and efficacy data of…
- Trial name
- NCT01640951
- Testing
- AIN457 150 mg, AIN457 300 mg
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 675 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
Add-on Enstilar to Otezla therapy.
- Trial name
- NCT03587194
- Testing
- Otezla
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Psoriasis
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the treatment of moderate to severe psoriasis in adults…
- Trial name
- NCT00251641
- Testing
- infliximab, methotrexate
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 [NCT00245765] and Week 12 of re-treatment in this study.
- Trial name
- NCT00329303
- Testing
- Certolizumab Pegol (Cimzia®)
- Where
- 14 sites in France, Germany
- Volunteers
- 71 people
- Sponsor
- UCB Pharma
Plaque Psoriasis
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis.
- Trial name
- AMAGINE-3 (NCT01708629)
- Testing
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab
- Where
- 157 sites in United States, Australia and 9 more
- Volunteers
- 1,881 people
- Sponsor
- Bausch Health Americas, Inc.
Arthritis, Rheumatoid, Colitis, Ulcerative
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.
- Conditions
- Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis
- Trial name
- NCT05796245
- Where
- Japan
- Volunteers
- 2,207 people
- Sponsor
- Pfizer
Stable Plaque Psoriasis
Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
This is an investigator-masked, randomized, parallel, clinical study comparing the efficacy of once daily versus twice daily application of Ultravate® ointment (halobetasol propionate 0.05% ointment) in combination with…
- Trial name
- NCT00990561
- Testing
- Ultravate ointment twice daily + LacHydrin lotion twice daily, Ultravate ointment once daily + LacHydrin lotion twice daily
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Grover's Disease, Psoriasis Vulgaris
Blue Light Phototherapy
This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
- Trial name
- NCT04343586
- Testing
- Blue light phototherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwestern University
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
- Trial name
- NCT01901185
- Testing
- Etanercept / Autoinjector A
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Amgen
Psoriasis, Psoriatic Arthritis
Prevalence and Incidence of Articular Symptoms and Signs Related to Psoriatic Arthritis in Patients With Psoriasis Severe or Moderate With Adalimumab Treatment
Psoriatic Arthritis (PsA) is a comorbidity that affects a significant proportion of participants with moderate or severe psoriasis.
- Trial name
- TOGETHER (NCT01316224)
- Where
- 15 sites in Colombia
- Volunteers
- 52 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of ABP 501 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT01970488
- Testing
- Adalimumab, ABP 501
- Where
- 3 sites in Australia, Canada and 1 more
- Volunteers
- 350 people
- Sponsor
- Amgen
Plaque Psoriasis
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 1 (NCT05223868)
- Testing
- JNJ-77242113
- Where
- 76 sites in United States, Canada and 8 more
- Volunteers
- 255 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis, Metabolic Syndrome
Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
People with psoriasis have significantly higher rates of obesity, diabetes, heart failure and high blood pressure than the general public.
- Conditions
- Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity
- Trial name
- NCT00477191
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
Psoriasis
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with…
- Trial name
- REFINE (NCT01313221)
- Testing
- etanercept, Topical agents
- Where
- 24 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Amgen
Psoriasis Vulgaris
Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis…
- Trial name
- NCT00764751
- Testing
- LEO 19123 Cream (calcipotriol plus LEO 80122), Dovonex® cream, Cream vehicle
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- LEO Pharma
Moderate to Severe Plaque-type Psoriasis
Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
This was an extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab.
- Trial name
- NCT01544595
- Testing
- Secukinumab (AIN457)
- Where
- 182 sites in United States, Argentina and 24 more
- Volunteers
- 1,147 people
- Sponsor
- Novartis Pharmaceuticals